The effect of penciclovir (BRL 39123) on the replication of varicella-zoster virus (VZV) in human embryonic lung fibroblasts (MRC-5 cells) was similar to aciclovir when the compounds were present continuously. However, when the compounds were withdrawn the antiviral activity of penciclovir was maintained more effectively than that of aciclovir. In the plaque reduction assay, median 50% effective concentrations (ECsos) were 3.8 I1g mr" for penciclovir and 4.2 I1g rnl" for aciclovir (n =29 clinical isolates). Similarly, penciclovir and aciclovir were equally effective in reducing the numbers of VZV-infected MRC-5 cells and in reducing VZV DNA synthesis within infected cells following continuous treatment. Within VZVinfected cells (S)-penciclovir-triphosphate was formed from penciclovir with >95% enantiomeric purity, and the concentration of penciclovir-triphosphate was 360-fold greater than aciclovir-triphosphate immediately after treatment. This phosphorylation ratio compensates for the lower affinity of VZV DNA polymerase for penciclovir-triphosphate compared with aciclovir-triphosphate (K;s =7.5 11M and 0.2 11M, respectively). When VZV-infected cultures were treated for 3 days, followed by withdrawal of the compound, inhibition of viral DNA synthesis by penciclovir was maintained for 24 h, whereas viral DNA synthesis resumed more readily after removal of aciclovir. Furthermore, following 8 h daily pulse treatment for 5 days, penciclovir was significantly more active than aciclovir in reducing VZV DNA synthesis (p =0.006, n =10 clinical isolates). The long intracellular half-life of penciclovir-triphosphate (9.1 h) compared with that of aciclovir-triphosphate (0.8 h)
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Introduction
Penciclovir (BRL 39123) is a potent and selective inhibitor of varicella-zoster virus (VZV) and herpes simplex virus (HSV-1 and HSV-2) in cell culture (Boyd et al., 1987; Boyd et al., 1993) . In the present study, the activity of penciclovir against clinical isolates of VZV has been assessed in several different antiviral assays and compared with that of aciclovir. Although it is standard practice to compare antiviral agents in assays where infected celfs are exposed continuously to the compounds, this bears little relationship to the changing plasma concentrations of an antiviral agent in a patient. Plasma concentrations of antiviral nucleosides vary considerably with time, depending on dose regimen and pharmacokinetics. Accordingly, the effect of treating VZV-infected cultures intermittently or for reduced periods with penciclovir or aciclovir was examined. Penciclovir was invariably more active than aciclovir under these conditions in HSVinfected cultures (Boyd et al., 1987; Earnshaw et al., 1992; Weinberg et el., 1992; Bacon and Schinazi, 1993; Vere Hodge and Cheng, 1993) .
The mechanism of action of penciclovir against herpesviruses has been reviewed (Vere Hodge and Cheng, 1993) . In the present report, further details of the mechanism of action against VZV are presented, including the elucidation of the chirality of penciclovir-triphosphate formed within VZV-infected cells and the inhibition of VZV DNA polymerase by penciclovir-triphosphate. In addition, to explain the differing effects on virus replication following Withdrawal of compounds, the relative stabilities of penciclovir-triphosphate and aciclovir-triphosphate within VZV-infected celfs were compared.
Results

Plaque reduction assay
Penciclovir and aciclovir were compared by the plaque reduction assay in tests against clinical isolates of VZV in of VZV infected cells, revealed only a single resonance at 61.9 p.p.m. In previous studies resonance at this position was shown to represent (S)-penciclovir-triphosphate , and resulted from phosphorylation at the 4' position, non-adjacent to the 13C label. No resonance at 66.5 p.p.m. which was known to arise from (R)-penciclovir-triphosphate was observed. From these results, an enantiomeric ratio of >95% (S)-penciclovirtriphosphate was assigned in view of the signal/noise limits of the 13C NMR spectrum. - (Table 2) .
Infectious centre assay
Both compounds inhibited the replication of VZV clinical isolate 41031 and were of similar activity, as judged by the infectious centre assay in MRC-5 cells ( Fig. 1 ). However, even at 10 J..Lg ml", the highest concentration tested, neither compound reduced the number of infectious centres by 99%; the ECgOwas 3.9 J..Lg mr" for penciclovlr and 5.6 J..Lg ml-1 for aciclovir. From three experiments, the mean ECgos (±S.D.) for penciclovir and aciclovir were 4.8 (±0.8) J..Lg rnr 1 and 8.0 (±5.1) J..Lg rnr", respectively.
Thymidine incorporation into uninfected cells
In an assay in Hs68 cells measuring the incorporation of 3H-thymidine into cellular DNA, IC so s for penciclovir and aciclovir were 100 J..Lg rnr' and 65 J..Lg ml", respectively.
Likewise, it was confirmed that penciclovir and aciclovir had no significant effect on thymidine incorporation into MRC-5 cells (IC so>100 J..Lg rnr').
MRC-5 (n = 29 isolates) ( Table 1 ). There were no significant differences in the median ECsos for penciclovir (3.8 J..Lg rnr") and aciclovir (4.2 J..Lg ml'") for the two compounds in MRC-5 cells. In addition, 12 of these clinical isolates were studied in another human fibroblast cell line, Hs68 cells. The compounds were about five-fold more active in Hs68 cells compared with MRC-5 cells (Table 1) , but again there were no differences between penciclovir and aciclovir, with median ECsos being 0.8 J..Lg ml-1 for both compounds. Although VZV plaques were not difficult to score in Hs68 monolayers, it was noted that the efficiency of plaque formation by the VZV strains was about five-fold lower in Hs68 cells than in MRC-5 cells.
Chirality of intracellular pencictovir-ttiphosphete
The phosphorylation of one of the hydroxymethyl groups of penciclovir creates a chiral centre with the possibility of forming 
aK; derived from Dixon plots (means of duplicate values). bMean intracellular half-life from two determinations (11.0 and 9.0 hours) combined with the value of 7.2 hours derived previously (Earnshaw et aI., 1992) . measured at various times subsequent to removing extracellular compound ( Fig. 3 ). Infected cells were treated for 18 h with [3Hlpenciclovir or [3Hlaciclovir to maintain consistency with an earlier study (Earnshaw et al., 1992) . Immediately after removal of extracellular compounds, the ..~~;;~z:
Effect on DNA synthesis following treatment withdrawal
To investigate whether antiviral activity could be maintained after withdrawal of extracellular compound, MRC-5 cell cultures infected at 0.01 pfu cell" were treated with penciclovir or aciclovir for 2 or 3 days, beginning from the time of infection, then re-incubated in the absence of compound. VZV DNA synthesis was measured on day 4, penciclovir-triphosphate concentration (121 pmol per million cells in comparative experiment, 262 pmol per million cells in a subsequent experiment) was 360-fold greater than for aciclovir-triphosphate (0.34 pmol per million cells). Aciclovir-triphosphate concentrations were below the level of detection (0.025 pmol per million cells) 4 h after removal of extracellular aciclovir. In contrast, penciclovir-triphosphate was still present in substantial amounts even after incubating the infected cells for 12 h ( Fig. 3 ) and 24 h (77 and 50 pmol per million cells, respectively) in drug-free medium.
In the present study the intracellular half-lives were 9.0 hand 11.0 h for penciclovir-triphosphate, determined in two experiments, and 0.8 h for aciclovir-triphosphate ( Table 2 ). The intracellular stability of penciclovir-triphosphate in VZV-infected MRC-5 cells is therefore far greater than for aciclovir-triphosphate (Table 2) 
Stability of penciclovir-triphosphate and aciclovir-triphosphate in VZV-infected cells. MRC-5 cells were infected with the VZV clinical isolate 23977 and, when the cytopathic effect was extensive, incubated with radiolabelled penciclovir or aciclovir for 18 h. Following the removal of extracellular compound the concentrations of the triphosphates were measured at the times indicated. By 4 h concentrations of aciclovir-triphosphate were below the level of detection (0.025 pmol per million cells) .
10 11 12 9 8 7 6 5 4 3 2 Penciclovir this being the time when peak viral DNA synthesis was observed. Control cultures were treated for the duration of the experiment (0-4 days). With penciclovir, treatment from 0-3 days was almost as effective as treatment from 0-4 days (Fig. 4) . Indeed, when the results were compared by a two-way analysis of variance, there was no significant difference between the 0-3 day and 0-4 day treatments for penciclovir. However, VZV DNA synthesis resumed more readily in cultures treated with penciclovir from 0-2 days. The ability of penciclovir at 0.3 I1g mr' to cause prolonged inhibition of VZV DNA synthesis was reduced compared with the higher concentrations tested (1,3 and 10 I1g ml-1 ) . For aciclovir, inhibition of VZV DNA synthesis was significantly inferior for the 0-3 day The areas under the dose-response curves for these pulse-treated cultures, were significantly lower for penciclovir than with acic/ovir (p = 0.001). Similarly, by comparing the ECsos, pulse treatment with penciclovir was shown to be significantly more effective than with aciclovir (p = 0.0006; Table 3 ). However, for cultures treated continuously the ECsos were similar for penciclovir and aciclovir (Table 3) . Thus, penciclovir was a more effective inhibitor of VZV DNA synthesis than aciclovir when the cultures were treated with the compounds for 8 h per day for 5 days.
regimen compared with that of the 0-4 day regimen (p < 0.001 at 1, 3 and 10 I1g mr': p = 0.016 at 0.3 I1g rnl"). These results suggest that in comparison with penciclovir, VZV DNA synthesis resumed more readily after withdrawal of extracellular aciclovir from the cultures. However, there was little difference between penciclovir and aciclovir when the compounds were present throughout the experiment.
"Number of isolates tested = 10. "Comparisons were made by the Student's paired t-test. MRC-5 cells were infected with VZV Ellen at 0.Q1 pfu cell" and treated with the compounds for the times shown (n = 3). Cultures were re·incubated in drug-free medium until day 4 when VZV DNA levels in all cultures were determined by hybridization. VZV DNA in the treated cultures was expressed as the mean percentage VZV DNA synthesis relative to the untreated virus control. Adapted from Bacon and Schinazi (1993) .
Discussion
In the present study, significant aspects of the mechanism of action of pencic/ovir and aciclovir against VZV were further investigated, and the cell culture activities of these compounds compared. An infectious centre assay, which is a very stringent test for an antiviral agent, was developed as a novel means of measuring the inhibition of VZV replication by penciclovir and aciclovir. The highly cell-associated nature of VZV (Schmidt and Lennette, 1976) makes it difficult to perform conventional virus yield reduction assays as can be done with HSV (Collins and Bauer, 1977; Boyd et al., 1987) , but the spread of virus within a VZV-infected culture cal"! be followed by using an infectious centre assay. In this assay, penciclovir and aciclovir had similar activity against VZV 41031 in MRC-5 cells treated continuously for 5 days (Fig. 1) . The results from plaque reduction assays in MRC-5 and Hs68 cells show that the relative activities of the two compounds against clinical isolates of VZV are very similar in both cell lines (Table 1) . In cytotoxicity assays, very high concentrations of penciclovir or aciclovir were required to inhibit thymidine incorporation by either MRC-5 or Hs68 cells. From these data, it is clear that both penciclovir and aciclovir are potent and selective inhibitors of VZV.
(8)-penciclovir-triphosphate, the enantiomer analogous to the natural nucleotide dGTP, has been reported to be a more effective inhibitor of HSV DNA polymerases than the (R) enantiomer (Earnshaw et al., 1992) . As has been previously observed for HSV-1 infected MRC-5 cells , penciclovir-triphosphate detected in VZV-infected cells was composed almost entirely of the (8) enantiomer (enantiomeric purity >95%). Thus, VZV infected cells behave more like HSV-1 infected cells than HSV-2 infected cells, which produced 90% (8) and 10% (R) penciclovir-triphosphate .
Aciclovir-triphosphate (K,= 0.2 J..lM) has a higher affinity for VZV DNA polymerase than penciclovir-triphosphate (Kj = 7.5 J..lM; Table 2 ). In a recent study Kjs for the inhibition of VZV DNA polymerase by pencl-c1ovir-triphosphate and aciclovir-triphosphate were lower than reported here (1.6 J..lM and 0.01 J..lM, respectively). The difference may be attributable to the use of recombinant enzyme by these authors . Both studies indicate that aciclovir-triphosphate is a more potent inhibitor of VZV DNA polymerase (38-160 fold). It should be noted, however, that levels of penciclovirtriphosphate in VZV-infected cells are much higher than for aciclovir-triphosphate. After treatment for 18 h at 10 J..lM penciclovir or aciclovir there was a 360-fold difference between the intracellular concentrations of penciclovirtriphosphate and aciclovir-triphosphate. Penciclovir and aciclovir have similar activity against VZV in a variety of different cell culture assays when the compounds are present continuously (Table 1, Fig. 1, Table 3 ). This observation suggests that the greater phosphorylation of penclclovir compensates for the higher Kj of VZV DNA polymerase for penciclovir triphosphate, consistent with earlier work on HSV-1 and HSV-2 (Vere Hodge and Perkins, 1989; Earnshaw et al., 1992) .
The intracellular half-life for penciclovir-triphosphate in
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VZV-infected cells (9.1 h) was similar to the value of 10 h determined previously for HSV-1 (Vere Hodge and Perkins, 1989) , but less than the 20 h half-life in cells infected with HSV-2 (Earnshaw et al., 1992) . It has been reported elsewhere that the intracellular half-lives of acyclic nucleotides show variability according to which virus is used . The longer half-life of penciclovir-triphosphate compared with aclclovir-trlphosphate becomes important after an antiviral state is established and the extracellular compounds have been removed.
In previous work with HSV-1 and HSV-2, penciclovir caused prolonged inhibition of viral replication (Boyd et al., 1987; Vere Hodge and Perkins, 1989; Earnshaw et al., 1992; Bacon and Schinazi, 1993) . In addition, repeated daily pulse treatment of HSV-infected cells has demonstrated that penciclovir has more prolonged antiviral activity than aciclovir (Weinberg et al., 1992) . In the present studies, pulse treatment of VZV-infected cultures with penciclovir reduced VZV DNA synthesis significantly more effectively than for aciclovir (Table 3 ). This result, together with the findings from the experiment, where treatment times were reduced (Fig. 4) , illustrates the prolonged antiviral activity of penciclovir, which occurs as a consequence of the intracellular stability of penciclovirtriphosphate.
Recent trials with famciclovir, the oral form of penciclovir, in patients with herpes zoster have demonstrated clinical benefits over aciclovir in terms of both efficacy and dosing convenience (Degreef et al., 1994) whilst maintaining a safety profile comparable to placebo (Saltzman et al., 1994) . Furthermore, famciclovir significantly reduced the duration of post-herpetic neuralgia when compared with placebo (Tyring et al., 1995) . Results from placebo-controlled studies with aciclovir have shown a variable effect of therapy on this complication of herpes zoster (Huff et al., 1988; McKendrick et et., 1989; Morton and Thomson, 1989) . The potent and selective inhibition of VZV replication in cell culture by penciclovir, coupled with the prolonged activity, is likely to contribute to the clinical efficacy of famciclovir.
Materials and Experimental Procedures
Cell culture MRC-5 cells (human embryonic lung fibroblasts) were cultured in growth medium consisting of Eagle's Minimal Essential Medium (EMEM) supplemented with 10% foetal calf serum (FCS). For the antiviral assays, MRC-5 cells in growth medium containing penicillin (100 IU mr") and streptomycin (100 Ilg rnl") were seeded into 24-well or 96-well plates. VZVinfected MRC-5 cells were incubated in assay medium consisting of EMEM supplemented with 5% heat-inactivated FCS and antibiotics. Hs68 cells (neonatal human foreskin fibroblasts) were prepared and used for antiviral assays as described for MRC-5 cells, except that Dulbecco's Modified Eagle's Medium was used in place of EMEM. Cell culture media, serum and other supplements were purchased from Gibco BRL, Paisley, UK.
Viruses
VZV Ellen was purchased from the American Type Culture Collection, Rockville, MA. Clinical isolates of VZV were provided by the following centres: Epsom Public Health Laboratory, Epsom, UK; Southampton General Hospital, Southampton, UK; Universitair Sint-Pietersziekenhuis, Brussels, Belgium and Smith Kline Beecham Clinical Laboratories, USA. Viruses were grown in MRC-5 cells and stored, either as ceil-associated virus in assay medium containing 10% dimethyl sulphoxide at -196 DC, or as cell-free virus at -85 DC in assay medium containing 10% sorbitol. Cell-free virus was prepared by sonication of infected cell suspensions prepared from MRC-5 cell monolayers exhlbitinq between 20 and 50% cytopathic effect. The cells were suspended in growth medium containing 10% sorbitol prior to sonication (Schmidt and Lennette, 1976) . Cellfree virus was used for all antiviral assays. The susceptibilities of individual strains used in the current studies towards penclclovir and aciclovir, are recorded in Table 4 for reference. Table 4 . Sensitivity of VZV to penciclovir and aciclovir in the plaque reduction assay in MRC-5 cells.
Plaque reduction assay
Plaque reduction assays in MRC-5 cells or Hs68 cells were as described previously (Boyd et al., 1987) , except cell monolayers were stained with 5% Giemsa in water (compounds were tested in duplicate). The 50% effective concentrations (ECsos) were calculated by interpolation from the fitted dose-response curves.
Infectious centre assay
MRC-5 cell monolayers in 24-well plates were infected with the VZV clinical isolate 41031 (Table 4) at 5 x 10 4 pfu cell-1 (approximately 100 pfu per well). After adsorption for 1 h at room temperature, the cultures were treated with dilutions of the test compounds prepared in assay medium (0.3-10 I1grnl') and incubated at 37°C for 5 days. Infectious centres were assayed by preparing and pooling replicate (n = 3) cell suspensions, and then titrating these in triplicate on indicator MRC-5 cell monolayers.
Cytotoxicity assay
Cells were seeded in growth medium in 96-well plates, and grown for 48 h with concentrations of penciclovir or aciclovir ranging from 0.03-100 I1g mr". Each was tested in triplicate. The cells were labelled with [6-3Hlthymidine for 5 h and then processed as before (Vere Hodge and Perkins, 1989) Aciclovir and penciclovir were prepared within the laboratories of SmithKline Beecham Pharmaceuticals. Both compounds were dissolved in dimethyl sulphoxide at 10 mg ml" and stored at -20 DC prior to dilution in cell culture medium. The [8-3Hlaciclovir (666 GBq mmor") was obtained from Moravek Biochemicals Inc., Brea, . Isotopically chiral [4'-13Clpenciclovir was prepared within SmithKline Beecham as described previously (Sime et al., 1992), and [4'-3Hlpenciclovlr (27.8 GBq rnmol") was prepared by the Synthetic Isotope Chemistry Unit, SmithKline Beecham Pharmaceuticals, Harlow, UK. Penciclovir-triphosphate used for DNA polymerase studies was extracted from HSV-2 infected cells (as described for HSV-1, Earnshaw et al., 1992) . This was previously shown to consist predominantly (90%) of the (8) enantiomer . Aciclovir-triphosphate was chemically synthesized by SmithKline Beecham Pharmaceuticals.
VZVDNApo~meroseswdffis MRC-5 cells were infected with a cell-associated virus preparation of the VZV clinical isolate 23977 (Table 4) , and then incubated until the cytopathic effect (cpe) was extensive (>60%). The cells were harvested and lysed in high salt buffer (Earnshaw et al., 1992) . The viral DNA polymerase was partially purified from cell Iysates by 50% ammonium sulphate precipitation and phosphocellulose lon-sxchanqe chromatography (Powell and Purifoy, 1977) . This partially purified VZV DNA polymerase was used in assays measuring the incorporation of a labelled nucleotide, [3HldGTP, into activated calf thymus DNA in the presence or absence of inhibitors (Earnshaw et al., 1992) . The K m was determined by testing polymerase activity in the presence of varying [3HldGTP concentrations. The Kj was measured by varying [3HldGTP and inhibitor concentrations (penciclovir-or aciclovir-triphosphate). Klenow DNA polymerase (Boehringer Mannheim, East Sussex, U.K.) was used as a positive control, 0.2 units of this enzyme were used reaction in place of VZV DNA polymerase. The reactions were terminated by the addition of trichloroacetic acid, and the resulting precipitated DNA was then filtered. The amount of [3HldGTP incorporated into the DNA was measured by scintillation counting on a Wallac Betaplate system.
The methods were modified from those described previously (Earnshaw et al., 1992) . In brief, MRC-5 cell monolayers in Virus strain 25 ern" flasks were infected with VZV clinical isolate 23977 (cell-associated virus). When cpe affected 60% of the monolayer the cultures were incubated with VZV assay medium (3 ml) containing either 10 IlM or 10 IlM [8-3Hlaciclovir (247 GBq mrnol", a mixture of labelled and unlabelled aciclovir). The specific activity of [8-3Hlaciclovir was increased from the 28 GBq rnmor' used previously (Earnshaw et a/., 1992) to 247 GBq mrnorl.whllst retaining the same overall chemical concentration of 10 IlM. After 18 h the cells were washed, and incubated with an excess (50 ml) of fresh assay medium for various times up to 12 h. After washing the cells with ice-cold phosphate buffered saline (PBS), phosphates were extracted into ice-cold phosphatebuffered ethanol (3 ml of 50% ethanol in 0.15 mM potassium dihydrogen phosphate/O.77 mM disodium hydrogen phosphate, pH 7.4) for 4 minutes and stored at -40 cC. Prior to HPLC analysis, the cell extracts were dried rapidly by centrifugal evaporation to prevent breakdown of the triphosphates. The dry extracts from penciclovir-treated cells were dissolved in 0.6 ml water. The dry extracts from aciclovir-treated cells were dissolved in a smaller volume of water (0.3 ml) to maximize sensitivity. All the extracts were stored at -40 "C.
Measurement of intracellular triphosphate concentrations and intracellular half-life
The concentrated extracts were analysed by ion exchange HPLC using a 100 x 4.6 mm Hydropore SAX column with a 30 x 4.6 mm guard cartridge (Anachem, Luton, UK), with a 10 mM to 125 mM ammonium hydrogen phosphate (pH 5.5) gradient containing 10% methanol throughout (column flow rate: 0.5 ml rnln"). Liquid scintillant (1.3 ml rnln") (Monoflow 3, National Diagnostics, Atlanta, GA) was introduced by means of a post-column T-piece and tritiated compounds were detected using a Ramona-5 radiochemical detector (Lablogic, Sheffield, UK). Peak identities were based on precise matching of retention times of chemically synthesized unlabelled penciclovirtriphosphate, and aciclovir-triphosphate standard solutions (which each contained some di-and mono-phosphates). The intracellular half-lives for penciclovir-triphosphate and aciclovirtriphosphate were determined using the following equation: 
Chirality of penciclovir triphosphate in VZV infected cells
The method for determination of penciclovir-triphosphate chirality in VZV infection was as previously reported for HSV-1 and HSV-2 infected cells (Vere Hodge et el., 1993 
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VZV DNA inhibition assays
In the first experiment, the effect of withdrawing treatment from infected cultures on subsequent VZV DNA synthesis was investigated. MRC-5 cells in 96-well plates were infected with VZV Ellen (Table 4 ) at 0.01 pfu cell-1 and treated with concentrations of the test compounds ranging from 0.3-10 Ilg mr" in assay medium. Extracellular compound was removed after the appropriate' treatment time, cell monolayers were washed: drug-free medium was added and the cultures were re-incubated. Four days after infection, levels of VZV DNA in the cell monolayers (n = 3) were determined by DNA hybridization. Cell Iysates were transferred to Hybond C-Extra filters (Amersham International pic, Little Chalfont, UK) using a dot-blot manifold, and the DNA was denatured (Gadler et al., 1984; Vere Hodge et a/., 1989) . The DNA probe used to detect VZV DNA was the Kpn1 dfragment cloned into pAT153, kindly provided by Prof. J. H. Subak-Sharpe, Glasgow University, UK. After hybridization with the 32P-labelled VZV-specific DNA probe, autoradiographs were prepared, the filters were cut up and the radioactivity associated with the individuallysates, was measured in a liquid scintillation counter.
In a subsequent series of experiments VZV DNA synthesis was measured after daily pulse treatment of infected cultures. Confluent MRC-5 cell mono layers in 96-well plates were infected with VZV clinical isolates in 0.1 ml PBS, at a concentration which produced greater than 50% cpe after 5 days incubation (approximately 200 pfu 0.1 mr'), Ten out of the 29 isolates tested in the plaque reduction assay in MRC-5 cells were randomly selected and the mean ECsos (±S.D.) were 6.3 ±5.4 Ilg mr' for penciclovir and 6.0 ±2.7 Ilg mr" for aciclovlr. The virus was adsorbed for 1 h at room temperature. The inoculum was then removed, and replaced with 0.2 ml of VZV assay medium containing either penciclovir or aciclovir diluted to give final concentrations' of between 1.0-100 Ilg mr' .
The infected cultures were treated for 8 h, the medium was then removed and the cell monolayers were washed in PBS. Fresh drug-free assay medium was added and the cultures were re-incubated until the following day when the pulse treatment was repeated. In this way, cultures were pulse-treated daily until day five. Parallel cultures were treated continuously for 5 days with the compounds at concentrations ranging from 0.3-10 Ilg mr'. In all assays the compounds were tested in triplicate, and untreated virus controls were included. After 5 days incubation, VZV DNA synthesis in the cultures was measured by DNA hybridization with a radiolabelled VZV-specific DNA probe (Hybrlwix! Probe System; Diagnostic Hybrids Inc., Ohio, USA). The DNA probe assay was performed in triplicate as described in the protocol supplied by Diagnostic Hybrids.
